COMPOSITION: Roxithromycin IP 150 mg
Drug class: Macrolides
- Roxithromycin is a derivative of the macrolide antibacterial erythromycin with in vitro antibacterial activity resembling that of the parent compound.
- As effective as more established treatments including erythromycin, amoxicillin/clavulanic acid and cefaclor.
- In vivo, roxithromycin is as effective or more effective than other macrolides in a wide range of infections.
- It is active against gram-positive and gram-negative cocci, gram-positive bacilli and some gram-negative bacilli, but has no significant effect on the predominant faecal flora.
- It also displays good activity against atypical pathogens, such as Mycobacterium avium complex, Helicobacter pylori and Borrelia spp.
- Roxithromycin significantly improved the signs and symptoms (in 3 months) of rheumatoid arthritis in adult patients and was generally well tolerated.